| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003078 | American Journal of Ophthalmology | 2012 | 7 Pages |
Abstract
In human nonvitrectomized eyes, the aqueous half-life of 0.5 mg intravitreally injected ranibizumab is 7.19 days, slightly shorter than the half-life of 9.82 days previously determined for bevacizumab by comparable methods.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Tim U. Krohne, Zengping Liu, Frank G. Holz, Carsten H. Meyer,